Anti-Fibrinogen antibody (ab27913)
Key features and details
- Rabbit polyclonal to Fibrinogen
- Suitable for: WB, ELISA, IHC-P
- Reacts with: Mouse
- Isotype: IgG
Get better batch-to-batch reproducibility with a recombinant antibody
- Research with confidence – consistent and reproducible results with every batch
- Long-term and scalable supply – powered by recombinant technology for fast production
- Success from the first experiment – confirmed specificity through extensive validation
- Ethical standards compliant – production is animal-free
Overview
-
Product name
Anti-Fibrinogen antibody
See all Fibrinogen primary antibodies -
Description
Rabbit polyclonal to Fibrinogen -
Host species
Rabbit -
Tested applications
Suitable for: WB, ELISA, IHC-Pmore details -
Species reactivity
Reacts with: Mouse -
Immunogen
Full length native protein (purified): Mouse fibrinogen isolated from plasma using several chromatographic steps.
-
General notes
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Upon delivery aliquot. Store at -80°C. Avoid freeze / thaw cycle. -
Storage buffer
Constituent: Whole serum -
Concentration information loading...
-
Purity
Whole antiserum -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab27913 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
Use at an assay dependent concentration.
|
|
ELISA |
Use at an assay dependent concentration.
|
|
IHC-P | (1) |
Use at an assay dependent concentration.
|
Notes |
---|
WB
Use at an assay dependent concentration. |
ELISA
Use at an assay dependent concentration. |
IHC-P
Use at an assay dependent concentration. |
Target
-
Function
Fibrinogen has a double function: yielding monomers that polymerize into fibrin and acting as a cofactor in platelet aggregation. -
Tissue specificity
Plasma. -
Involvement in disease
Defects in FGA are a cause of congenital afibrinogenemia (CAFBN) [MIM:202400]. This is a rare autosomal recessive disorder characterized by bleeding that varies from mild to severe and by complete absence or extremely low levels of plasma and platelet fibrinogen. Note=The majority of cases of afibrinogenemia are due to truncating mutations. Variations in position Arg-35 (the site of cleavage of fibrinopeptide a by thrombin) leads to alpha-dysfibrinogenemias.
Defects in FGA are a cause of amyloidosis type 8 (AMYL8) [MIM:105200]; also known as systemic non-neuropathic amyloidosis or Ostertag-type amyloidosis. AMYL8 is a hereditary generalized amyloidosis due to deposition of apolipoprotein A1, fibrinogen and lysozyme amyloids. Viscera are particularly affected. There is no involvement of the nervous system. Clinical features include renal amyloidosis resulting in nephrotic syndrome, arterial hypertension, hepatosplenomegaly, cholestasis, petechial skin rash. -
Sequence similarities
Contains 1 fibrinogen C-terminal domain. -
Domain
A long coiled coil structure formed by 3 polypeptide chains connects the central nodule to the C-terminal domains (distal nodules). The long C-terminal ends of the alpha chains fold back, contributing a fourth strand to the coiled coil structure. -
Post-translational
modificationsThe alpha chain is not glycosylated.
Forms F13A-mediated cross-links between a glutamine and the epsilon-amino group of a lysine residue, forming fibronectin-fibrinogen heteropolymers.
About one-third of the alpha chains in the molecules in blood were found to be phosphorylated.
Conversion of fibrinogen to fibrin is triggered by thrombin, which cleaves fibrinopeptides A and B from alpha and beta chains, and thus exposes the N-terminal polymerization sites responsible for the formation of the soft clot. The soft clot is converted into the hard clot by factor XIIIA which catalyzes the epsilon-(gamma-glutamyl)lysine cross-linking between gamma chains (stronger) and between alpha chains (weaker) of different monomers.
Phosphorylation sites are present in the extracellular medium. -
Cellular localization
Secreted. - Information by UniProt
-
Database links
- Entrez Gene: 110135 Mouse
- Entrez Gene: 14161 Mouse
- Entrez Gene: 99571 Mouse
- SwissProt: Q8K0E8 Mouse
- SwissProt: Q8VCM7 Mouse
-
Alternative names
- FGA antibody
- FGB antibody
- FGG antibody
see all
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
Datasheet download
References (9)
ab27913 has been referenced in 9 publications.
- Shi C et al. Neutrophil circadian rhythm is associated with different outcomes of acute kidney injury due to cholesterol crystal embolism. Front Cardiovasc Med 9:974759 (2022). PubMed: 35966530
- Kerr BA et al. Platelet TSP-1 controls prostate cancer-induced osteoclast differentiation and bone marrow-derived cell mobilization through TGFß-1. Am J Clin Exp Urol 9:18-31 (2021). PubMed: 33816691
- Hulmi JJ et al. Muscle NAD+ depletion and Serpina3n as molecular determinants of murine cancer cachexia-the effects of blocking myostatin and activins. Mol Metab 41:101046 (2020). PubMed: 32599075
- Li X et al. Deficiency of Mouse FHR-1 Homolog, FHR-E, Accelerates Sepsis, and Acute Kidney Injury Through Enhancing the LPS-Induced Alternative Complement Pathway. Front Immunol 11:1123 (2020). PubMed: 32636836
- Uyama N et al. Anti-interleukin-6 receptor antibody treatment ameliorates postoperative adhesion formation. Sci Rep 9:17558 (2019). PubMed: 31772282
- Masuda H et al. Batroxobin accelerated tissue repair via neutrophil extracellular trap regulation and defibrinogenation in a murine ischemic hindlimb model. PLoS One 14:e0220898 (2019). PubMed: 31419236
- Wan H et al. Role of von Willebrand factor and ADAMTS-13 in early brain injury after experimental subarachnoid hemorrhage. J Thromb Haemost 16:1413-1422 (2018). PubMed: 29729651
- Zhang Y et al. Inverse agonist of ERR? reduces cannabinoid receptor type 1-mediated induction of fibrinogen synthesis in mice with a high-fat diet-intoxicated liver. Arch Toxicol 92:2885-2896 (2018). PubMed: 30019168
- Nordstrom SM et al. Increased thrombosis susceptibility and altered fibrin formation in STAT5-deficient mice. Blood 116:5724-33 (2010). WB ; Mouse . PubMed: 20823455